In 1992, Dr. Semenza and Dr. Wang at Johns Hopkins University discovered a molecule that is necessary for the transcriptional activation of the erythropoietin (EPO) gene under hypoxic conditions in a liver cancer cell line (Hep3B), and named it HIF-1 [2,15]. This evidence concerns the gene EPO and liver cancer.